Read by QxMD icon Read

Advances in Triple Negative Breast Cancer

shared collection
23 papers 0 to 25 followers My collection gathers the most important recent advances in the field of TNBC.
Ke Wang, Jianjun Xu, Tao Zhang, Dan Xue
Tumor-infiltrating lymphocytes (TILs) influence tumor prognosis and the chemotherapeutic response. Here, we quantified the clinical relevance of TILs, including the effect of TILs on lymphocyte subpopulations and assessed their consistency in breast cancer. We searched published literature from January 2000 to January 2016. The main parameters analyzed were pathological complete response (pCR) and survival outcome following chemotherapy in patients with breast cancer. Pooled odds ratio (OR) or relative risk (RR) values with 95% confidence intervals (CIs) were computed using random and fixed-effects models...
July 12, 2016: Oncotarget
Elizabeth Pham, Melissa Yin, Christian G Peters, Christina R Lee, Donna Brown, Ping Xu, Shan Man, Lata Jayaraman, Ellen Rohde, Annabelle Chow, Douglas Lazarus, Scott Eliasof, F Stuart Foster, Robert S Kerbel
VEGF pathway-targeting antiangiogenic drugs, such as bevacizumab, when combined with chemotherapy have changed clinical practice for the treatment of a broad spectrum of human cancers. However, adaptive resistance often develops, and one major mechanism is elevated tumor hypoxia and upregulated hypoxia-inducible factor-1α (HIF1α) caused by antiangiogenic treatment. Reduced tumor vessel numbers and function following antiangiogenic therapy may also affect intratumoral delivery of concurrently administered chemotherapy...
August 1, 2016: Cancer Research
M A O'Rorke, L J Murray, J S Brand, N Bhoo-Pathy
BACKGROUND: The value of adjuvant radiotherapy in triple negative breast cancer (TNBC) remains unclear. A systematic review and meta-analysis was conducted in TNBC patients to assess survival and recurrence outcomes associated with radiotherapy following either breast conserving therapy (BCT) or post-mastectomy radiotherapy (PMRT). METHODS: Four electronic databases were searched from January 2000 to November 2015 (PubMed, MEDLINE, EMBASE and Web of Science). Studies investigating overall survival and/or recurrence in TNBC patients according to radiotherapy administration were included...
June 2016: Cancer Treatment Reviews
Fatima Zahra Mouh, Mohammed El Mzibri, Meriem Slaoui, Mariam Amrani
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng, Vassiliki Karantza, Laurence Buisseret
PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. METHODS: KEYNOTE-012 ( identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizumab given intravenously at 10 mg/kg every 2 weeks to patients with advanced PD-L1-positive (expression in stroma or ≥ 1% of tumor cells by immunohistochemistry) TNBC, gastric cancer, urothelial cancer, and head and neck cancer...
July 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Ahmet Cinkaya, Mustafa Akin, Adem Sengul
PURPOSE: Breast cancer is the most common cancer in women. Treatment responses are variable depending on tumor morphological characteristics, clinical characteristics, and hormonal receptor levels. In current medical practice, estrogen receptor (ER), progesterone receptor (PGR), and human epidermal growth factor receptor 2 (HER2) levels have been identified as important prognostic factors; they can change prognosis and treatment modalities. In this study, the prognostic factors of patients with triple-negative breast cancer (TNBC) were examined retrospectively...
January 2016: Journal of Cancer Research and Therapeutics
Giorgio Mustacchi, Michelino De Laurentiis
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC...
2015: Drug Design, Development and Therapy
Antonio Marrazzo, Giovanni Boscaino, Emilia Marrazzo, Pietra Taormina, Antonio Toesca
INTRODUCTION: The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). METHODS: We evaluated the cohort of 612 consecutive women affected by early breast cancer...
September 2015: International Journal of Surgery
Bing Feng, Zhiai Xu, Fangyuan Zhou, Haijun Yu, Qianqian Sun, Dangge Wang, Zhaohui Tang, Haiyang Yu, Qi Yin, Zhiwen Zhang, Yaping Li
Despite considerable progress being made in breast cancer therapy, the complete eradication of highly aggressive triple negative breast cancer (TNBC) remains a notable challenge today. We herein report on the fabrication of novel gold nanorods (GNRs) with covalent cisplatin-polypeptide wrapping and folic acid (FA) conjugation (FA-GNR@Pt) for the targeted photothermal (PT) therapy and chemotherapy of TNBC. The FA-GNR@Pt hybrid nanoparticles are designed to integrate the photothermal conversion property of GNRs, the superior biocompatibility of polypeptide poly(l-glutamic acid) (PGA), the chemotoxicity of cisplatin, and the tumor targeting ability of FA into one single nanoplatform...
September 28, 2015: Nanoscale
Peter Kern, Anne Kalisch, Gunter von Minckwitz, Carolin Pütter, Hans-Christian Kolberg, Dirk Pott, Christian Kurbacher, Mahdi Rezai, Rainer Kimmig
INTRODUCTION: Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. PATIENTS AND METHODS: In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens...
June 2016: Journal of Chemotherapy
Jessica Firger
No abstract text is available yet for this article.
August 2015: Journal of the National Cancer Institute
Alexey Stupnikov, Galina V Glazko, Frank Emmert-Streib
BACKGROUND: Data from RNA-seq experiments provide a wealth of information about the transcriptome of an organism. However, the analysis of such data is very demanding. In this study, we aimed to establish robust analysis procedures that can be used in clinical practice. METHODS: We studied RNA-seq data from triple-negative breast cancer patients. Specifically, we investigated the subsampling of RNA-seq data. RESULTS: The main results of our investigations are as follows: (1) the subsampling of RNA-seq data gave biologically realistic simulations of sequencing experiments with smaller sequencing depth but not direct scaling of count matrices; (2) the saturation of results required an average sequencing depth larger than 32 million reads and an individual sequencing depth larger than 46 million reads; and (3) for an abrogated feature selection, higher moments of the distribution of all expressed genes had a higher sensitivity for signal detection than the corresponding mean values...
October 2015: Chinese Journal of Cancer
Atsuko Yamada, Shinji Osada, Toshiyuki Tanahashi, Satoshi Matsui, Yoshiyuki Sasaki, Yoshihiro Tanaka, Naoki Okumura, Nobuhisa Matsuhashi, Takao Takahashi, Kazuya Yamaguchi, Kazuhiro Yoshida
To evaluate a novel therapy for triple-negative breast cancer (TNBC), the biological responses to vitamin K3 (VK3) should be considered with the understanding of the features of breast cancer. In human breast cancer cell lines, the effects of VK3 on cell growth inhibition and the cellular signaling pathway were determined by MTT assay and western blotting. In the in vivo study, a subcutaneous tumor model of breast cancer was created, VK3 was injected into the subcutaneous tumors, and tumor size was measured...
October 2015: International Journal of Oncology
Sergio Granados-Principal, Yi Liu, Maria L Guevara, Elvin Blanco, Dong Soon Choi, Wei Qian, Tejal Patel, Angel A Rodriguez, Joseph Cusimano, Heidi L Weiss, Hong Zhao, Melissa D Landis, Bhuvanesh Dave, Steven S Gross, Jenny C Chang
INTRODUCTION: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with no effective targeted therapy. Inducible nitric oxide synthase (iNOS) is associated with poor survival in patients with breast cancer by increasing tumor aggressiveness. This work aimed to investigate the potential of iNOS inhibitors as a targeted therapy for TNBC. We hypothesized that inhibition of endogenous iNOS would decrease TNBC aggressiveness by reducing tumor initiation and metastasis through modulation of epithelial-mesenchymal transition (EMT)-inducing factors...
2015: Breast Cancer Research: BCR
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad
Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting...
June 2015: Cancer Biology & Medicine
Mehra Golshan, Constance T Cirrincione, William M Sikov, Donald A Berry, Sara Jasinski, Tracey F Weisberg, George Somlo, Clifford Hudis, Eric Winer, David W Ollila
OBJECTIVE: To assess the efficacy of neoadjuvant systemic therapy (NST) at increasing the rate of successful breast-conserving therapy (BCT) in triple negative breast cancer. BACKGROUND: Inducing tumor regression to permit BCT is often cited to support administration of NST. To quantify this benefit, we conducted a surgical companion study to CALGB40603, a randomized phase II, 2×2 factorial trial of neoadjuvant paclitaxel ± carboplatin ± bevacizumab (B) followed by doxorubicin plus cyclophosphamide ± B in stage II-III triple negative breast cancer...
September 2015: Annals of Surgery
David de Gonzalo-Calvo, Laura López-Vilaró, Laura Nasarre, Maitane Perez-Olabarria, Tania Vázquez, Daniel Escuin, Lina Badimon, Agusti Barnadas, Enrique Lerma, Vicenta Llorente-Cortés
BACKGROUND: The metabolic effect of intratumor cholesteryl ester (CE) in breast cancer remains poorly understood. The objective was to analyze the relationship between intratumor CE content and clinicopathological variables in human breast carcinomas. METHODS: We classified 30 breast carcinoma samples into three subgroups: 10 luminal-A tumors (ER+/PR+/Her2-), 10 Her-2 tumors (ER-/PR-/Her2+), and 10 triple negative (TN) tumors (ER-/PR-/Her2-). We analyzed intratumor neutral CE, free cholesterol (FC) and triglyceride (TG) content by thin layer chromatography after lipid extraction...
2015: BMC Cancer
Patricia de Cremoux, Mathieu Dalvai, Olivia N'Doye, Fatima Moutahir, Gaëlle Rolland, Olfa Chouchane-Mlik, Franck Assayag, Jacqueline Lehmann-Che, Laurence Kraus-Berthie, André Nicolas, Brian Paul Lockhart, Elisabetta Marangoni, Hugues de Thé, Stéphane Depil, Kerstin Bystricky, Didier Decaudin
Several publications have suggested that histone deacetylase inhibitors (HDACis) could reverse the repression of estrogen receptor alpha (ERα) in triple-negative breast cancer (TNBC) cell lines, leading to the induction of a functional protein. Using different HDACis, vorinostat, panobinostat, and abexinostat, we therefore investigated this hypothesis in various human TNBC cell lines and patient-derived xenografts (PDXs). We used three human TNBC cell lines and three PDXs. We analyzed the in vitro toxicity of the compounds, their effects on the hormone receptors and hormone-related genes and protein expression both in vitro and in vivo models...
January 2015: Breast Cancer Research and Treatment
Giuseppina Rosaria Rita Ricciardi, Barbara Adamo, Antonio Ieni, Luana Licata, Roberta Cardia, Giuseppa Ferraro, Tindara Franchina, Giovanni Tuccari, Vincenzo Adamo
BACKGROUND: TNBC is an aggressive subset of breast cancer (BC) without specific target therapy. METHODS: This observational, retrospective study included 45 cases of TNBC. The aim of this study was to evaluate the expression of the AR, E-cadherin and Ki-67 in relation to histological type, time to relapse and overall survival (OS). Immunohistochemistry (IHC) was carried out on formalin-fixed paraffin-embedded tumor samples obtained from patients defined TNBC. RESULTS: The AR was positive (IHC >10%) in 26...
2015: PloS One
Sherri Z Millis, Zoran Gatalica, Josiah Winkler, Semir Vranic, Jeffery Kimbrough, Sandeep Reddy, Joyce A O'Shaughnessy
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS: We evaluated 6341 (2111 TNBC and 4230 non-TNBC) breast cancer samples at a central laboratory for biomarkers of potential drug response across multiple platforms, including gene sequencing, protein expression, and gene copy number...
December 2015: Clinical Breast Cancer
2015-06-10 16:12:12
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"